For families living with Dravet syndrome, the journey often begins with a terrifying milestone: a prolonged, fever-related seizure in the first year of life. What starts as a frightening "first" quickly evolves into a complex, lifelong management of treatment resistant epilepsy. However, we are entering a transformative era in rare epilepsy research. We are moving away from broad-spectrum treatments and toward precision medicine—a shift that promises to address the underlying cause of the condition rather than just the symptoms.
At Science 37, we recognize that for a child with Dravet syndrome, a trip to a distant research hospital isn't just a commute; it’s a high-stakes logistical challenge that can trigger the very seizure clusters families work so hard to avoid. That is why the future of Dravet care isn't just about better science—it’s about better access through at-home clinical trials.
To understand the evolution of care, we must look at the biological blueprint of the condition. Approximately 80% of those diagnosed with Dravet syndrome have a mutation in the SCN1A gene. This gene is responsible for creating a protein that forms a "sodium channel" in the brain.
Think of these channels as the gatekeepers of electrical signals. In a typical brain, these gates open and close to keep electrical activity balanced. With an SCN1A mutation, these gates don't function correctly, specifically within inhibitory neurons—the cells meant to "calm" brain activity. When the "brakes" of the brain fail, the result is over-excitation, leading to frequent and often prolonged seizures.
Because this is a genetic issue, researchers are now focusing on precision medicine. This means developing therapies that specifically target the SCN1A pathway or attempt to restore the function of those sodium channels. It is a shift from "stopping a seizure" to "fixing the signaling error" at its source.
In the past, participating in rare epilepsy research meant traveling to specialized centers, often located hundreds of miles away. For a child with Dravet syndrome, this presents significant risks:
These barriers often meant that only a small, specific group of people could participate in research. This is where decentralized clinical trials are changing the landscape. By bringing the study to the patient, we can collect more accurate, "real-world" data while keeping the child in a safe, controlled environment.
One of the most unique aspects of Dravet syndrome is temperature sensitivity. A slight rise in core body temperature—whether from a fever, physical activity, or a warm day—can trigger a seizure. As we look toward future treatments, daily management remains the cornerstone of care.
Do:
Don’t:
The progress we’ve seen in neurological disorders over the last decade is a direct result of families choosing to participate in clinical trials for kids. However, we know that for your family to participate, the process must be patient-centric.
Through Science 37, at-home clinical trials allow for virtual visits with specialists, local nursing support, and wearable technology that monitors activity without the need for a hospital stay. This model ensures that rare epilepsy research is inclusive, reaching families regardless of their zip code.
By joining a study, you aren't just seeking a new option for your child; you are helping to refine the precision medicine that will define the next generation of Dravet syndrome care.
What makes Dravet syndrome different from other types of epilepsy? Dravet syndrome usually begins in the first year of life with prolonged seizures, often triggered by fever. Unlike many other epilepsies, it is highly resistant to standard medications and is frequently associated with the SCN1A gene mutation, leading to developmental and movement challenges over time.
Can my child participate in a trial if we don't live near a major city? Yes. Science 37 specializes in decentralized research, which means many of the requirements of a study—such as check-ins and data monitoring—can be done from your home, making clinical trials accessible to families everywhere.
Is precision medicine only for people with the SCN1A mutation? While many current "targeted" therapies focus on the SCN1A mutation, research is also expanding into other pathways that affect how neurons communicate. Every trial contributes to a broader understanding of how to stabilize the brain's electrical activity.
How does at-home research keep my child safe? At-home trials reduce the stress and environmental triggers associated with travel. Participants are monitored closely by a mobile clinical team and use telehealth to stay in constant contact with investigators, ensuring that the child’s safety and the family's comfort are the top priorities.
The evolution of Dravet syndrome care is moving fast. We are no longer just guessing which medications might work; we are using the SCN1A mutation as a roadmap to find answers. If you are interested in seeing how your family can contribute to these new frontiers in research, we invite you to explore our current offerings.
Together, we can move closer to a world where seizure clusters are a thing of the past and precision medicine is the standard for every child. Visit the Science 37 platform today to learn more about our current clinical trials and how you can get involved from the comfort of your own home.
